Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.48 |
| ▸ | PPARG known ✓ | P37231 | 7/20 | 0.46 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.46 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.46 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.46 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025181 | 0.98 | — | — | |
| SCHEMBL28178634 | 0.95 | AKR1B1 (0.48) | AKR1B1MEN1KMT2ACYP2C19GLA | |
| SCHEMBL8503813 | 0.95 | AKR1B1 (0.48) | AKR1B1MEN1KMT2ACYP2C19GLA | |
| SCHEMBL27609852 | 0.95 | AKR1B1 (0.48) | AKR1B1MEN1KMT2ACYP2C19GLA | |
| Hydrochloric Acid SCHEMBL28197489 | 0.93 | AKR1B1 (0.52) | AKR1B1MEN1KMT2ACYP2C19GPR84 | |
| Hydrochloric Acid SCHEMBL16059309 | 0.91 | ADRA1A (0.55) | AKR1B1MEN1KMT2AGPR84PPARG | |
| Hydrochloric Acid SCHEMBL29141184 | 0.91 | ADRA1A (0.55) | AKR1B1MEN1KMT2AGPR84PPARG | |
| SCHEMBL7563969 | 0.91 | AKR1B1 (0.54) | AKR1B1MEN1KMT2ACYP2C19GPR84 | |
| SCHEMBL11540844 | 0.88 | ADRA1A (0.57) | AKR1B1MEN1KMT2AGPR84PPARG | |
| SCHEMBL9259807 | 0.88 | ADRA1A (0.57) | AKR1B1MEN1KMT2AGPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20240058455-A1 | BIOORTHOGONAL LINKERS AND REACTIONS | THE GENERAL HOSPITAL CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230098031-A1 | METHODS FOR CELL IMAGING | THE GENERAL HOSPITAL CORPORATION | 2023-03-30 | — | — | US | disclosed |
| EP-4073064-A1 | METHODS FOR CELL IMAGING | The General Hospital Corporation (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022072949-A2 | BIOORTHOGONAL LINKERS AND REACTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-04-07 | — | — | WO | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| WO-2021119268-A1 | METHODS FOR CELL IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-9328088-B2 | Luminescent probes for biological labeling and imaging, and process for preparing the same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140228553-A1 | LUMINESCENT PROBES FOR BIOLOGICAL LABELING AND IMAGING, METHOD FOR PREPARING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-08-14 | — | — | US | disclosed |
| US-20140213777-A1 | LUMINESCENT PROBES FOR BIOLOGICAL LABELING AND IMAGING, AND PROCESS FOR PREPARING THE SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-07-31 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20100285120-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1694775-A1 | REAGENT FOR DETECTING AN ANALYTE | Precisense A/S (DK) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005059037-A1 | REAGENT FOR DETECTING AN ANALYTE | PRECISENSE A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| EP-0324109-A2 | 6-substituted mitomycin analogs | UNIVERSITY PATENTS, INC. (US) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058455-A1 | BIOORTHOGONAL LINKERS AND REACTIONS | TTI2, TKFC, TAOK1 | GLA 801/4885PPARG 3109/4885HDAC11 1470/4885 |
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | GLA 3024/4885PPARG 3973/4885HDAC11 1725/4885 |
| US-20140213777-A1 | LUMINESCENT PROBES FOR BIOLOGICAL LABELING AND IMAGING, AND PROCESS FOR PREPARING THE SAME | SLC30A6, SLC30A7, SLC39A7 | GLA 79/4885PPARG 2365/4885HDAC11 4604/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | GLA 3024/4885PPARG 3973/4885HDAC11 1725/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | GLA 3024/4885PPARG 3973/4885HDAC11 1725/4885 |
| US-20100285120-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | GLA 511/4885PPARG 2423/4885HDAC11 2098/4885 |
| US-20230098031-A1 | METHODS FOR CELL IMAGING | F13A1, MAN1B1, LPAR3 | GLA 569/4885PPARG 4783/4885HDAC11 2637/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | GLA 3024/4885PPARG 3973/4885HDAC11 1725/4885 |
| US-20140228553-A1 | LUMINESCENT PROBES FOR BIOLOGICAL LABELING AND IMAGING, METHOD FOR PREPARING SAME | SLC39A7, SLC30A7, SLC30A6 | GLA 124/4885PPARG 2995/4885HDAC11 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.